YL-13027 for Solid Tumors

Phase 1

Waitlist Available

Led By Trisha Wi Draper, Ph D

Research Sponsored by Shanghai YingLi Pharmaceutical Co. Ltd.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up throughout the study for approximately 2 years

Awards & highlights

No Placebo-Only Group

Summary

This trial tests a new drug called YL-13027 in patients with advanced solid tumors. The goal is to see if the drug is safe and effective in shrinking or stopping tumor growth. Patients in the study have limited treatment options and may not respond well to existing therapies.

Eligible Conditions

Solid Tumors

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ throughout the study for approximately 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~throughout the study for approximately 2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and throughout the study for approximately 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Frequency, duration and severity of Adverse Events and Serious Adverse Events

Secondary study objectives

Clinical Benefit Rate

DOR

Duration of Stable Disease

+3 more

Other study objectives

Plasma tumor antigens

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: YL-13027Experimental Treatment1 Intervention

YL-13027 is a novel small molecule TGF-βR1 inhibitor. 1.1.1. Chemical Properties Chemical Name: 6-(5-fluoro-2-(6-methylpyridin-2-yl)phenyl)imidazo\[1,2-a\]pyridine-3-carboxamide Molecular Formula C20H15FN4O Molecular Weight 346.36 Formulation YL-13027 is provided as pink film coated tablets for oral administration in two strengths, 30 mg and 120 mg. Packaging and Storage YL-13027 tablets are packaged (30 tablets/bottle) in the 45 mL opaque HDPE bottles with child resistant polypropylene caps, induction-sealed inner polypropylene liners. YL-13027 tablets should be protected from light in a closed container and stored at room temperature. Stability The shelf-life of YL-13027 oral tablets is tentatively set at 24 months when stored at room temperature.

Do I qualify?Apply below to find out